Nisa Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$26M Buy
58,183
+1,589
+3% +$741K 0.1% 133
2025
Q4
$25.7M Buy
56,594
+816
+1% +$352K 0.08% 141
2025
Q3
$21.8M Sell
55,778
-9,639
-15% -$4.03M 0.08% 154
2025
Q2
$29.1M Sell
65,417
-2,883
-4% -$1.33M 0.13% 118
2025
Q1
$33.1M Sell
68,300
-1,922
-3% -$896K 0.17% 111
2024
Q4
$28.3M Sell
70,222
-5,128
-7% -$2.38M 0.11% 146
2024
Q3
$35M Buy
75,350
+2,221
+3% +$1.07M 0.21% 102
2024
Q2
$34.3M Buy
73,129
+2,662
+4% +$1.16M 0.22% 92
2024
Q1
$29.5M Sell
70,467
-6,158
-8% -$2.6M 0.19% 114
2023
Q4
$31.2M Sell
76,625
-222
-0.3% -$82K 0.22% 99
2023
Q3
$26.7M Sell
76,847
-2,875
-4% -$1.01M 0.2% 113
2023
Q2
$28.1M Sell
79,722
-1,733
-2% -$584K 0.21% 109
2023
Q1
$25.7M Buy
81,455
+1,925
+2% +$577K 0.2% 118
2022
Q4
$23M Sell
79,530
-1,550
-2% -$472K 0.18% 133
2022
Q3
$23.5M Buy
81,080
+4,999
+7% +$1.44M 0.2% 109
2022
Q2
$21.4M Buy
76,081
+1,014
+1% +$271K 0.19% 119
2022
Q1
$19.6M Sell
75,067
-10,995
-13% -$2.61M 0.14% 146
2021
Q4
$20.9M Sell
86,062
-5,652
-6% -$1.1M 0.16% 142
2021
Q3
$16.6K Sell
91,714
-11,072
-11% -$2.16M 0.1% 186
2021
Q2
$20.7K Buy
102,786
+2,312
+2% +$484K 0.13% 154
2021
Q1
$21.6K Buy
100,474
+440
+0.4% +$96.6K 0.14% 143
2020
Q4
$23.6M Sell
100,034
-4,768
-5% -$1.09M 0.15% 151
2020
Q3
$28.5M Sell
104,802
-25,566
-20% -$7.05M 0.23% 99
2020
Q2
$37.8M Buy
130,368
+18,646
+17% +$5.06M 0.35% 64
2020
Q1
$26.6M Buy
111,722
+8,217
+8% +$1.88M 0.3% 77
2019
Q4
$22.7M Buy
103,505
+8,288
+9% +$1.68M 0.19% 118
2019
Q3
$16.1M Sell
95,217
-6,053
-6% -$1.07M 0.14% 156
2019
Q2
$18.6M Sell
101,270
-4,863
-5% -$850K 0.18% 122
2019
Q1
$19.5M Buy
106,133
+3,380
+3% +$624K 0.19% 116
2018
Q4
$17M Sell
102,753
-2,601
-2% -$451K 0.19% 123
2018
Q3
$20.3M Buy
105,354
+13,117
+14% +$2.34M 0.19% 125
2018
Q2
$15.7M Buy
92,237
+1,654
+2% +$256K 0.16% 149
2018
Q1
$14.8M Buy
90,583
+701
+0.8% +$115K 0.15% 146
2017
Q4
$13.5M Buy
89,882
+11,489
+15% +$1.7M 0.14% 164
2017
Q3
$11.9M Buy
78,393
+10,743
+16% +$1.62M 0.13% 170
2017
Q2
$8.64M Buy
67,650
+650
+1% +$78.2K 0.1% 214
2017
Q1
$7.33M Buy
67,000
+6,315
+10% +$556K 0.09% 245
2016
Q4
$4.47M Sell
60,685
-1,190
-2% -$96.8K 0.05% 346
2016
Q3
$5.4M Sell
61,875
-1,500
-2% -$142K 0.07% 297
2016
Q2
$5.45M Buy
63,375
+11,375
+22% +$983K 0.07% 284
2016
Q1
$4.13M Sell
52,000
-2,300
-4% -$208K 0.06% 335
2015
Q4
$6.83M Buy
54,300
+4,100
+8% +$495K 0.1% 209
2015
Q3
$5.33M Buy
50,200
+50
+0.1% +$6.42K 0.08% 253
2015
Q2
$6.19M Sell
50,150
-2,800
-5% -$353K 0.09% 226
2015
Q1
$6.25M Sell
52,950
-700
-1% -$83.9K 0.09% 234
2014
Q4
$6.37M Sell
53,650
-300
-0.6% -$33.8K 0.09% 230
2014
Q3
$6.06M Sell
53,950
-500
-0.9% -$47.6K 0.08% 230
2014
Q2
$5.16M Sell
54,450
-4,800
-8% -$337K 0.07% 264
2014
Q1
$4.19M Buy
59,250
+4,900
+9% +$388K 0.06% 321
2013
Q4
$4.04M Sell
54,350
-1,800
-3% -$125K 0.06% 317
2013
Q3
$4.26M Sell
56,150
-100
-0.2% -$7.96K 0.07% 287
2013
Q2
$4.5M Buy
+56,250
New +$4.14M 0.07% 255

Other funds holding VRTX

Nisa Investment Advisors's VRTX Position: Q1 2026 in Review

Nisa Investment Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q1 2026, buying an estimated $741K and bringing the position to 58,183 shares worth $26M. The position accounts for 0.1% of the portfolio, ranked #133.

Nisa Investment Advisors first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.8M in Q2 2020. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Nisa Investment Advisors held 58,183 shares of Vertex Pharmaceuticals worth $26M as of Q1 2026.
  • Nisa Investment Advisors bought 1,589 Vertex Pharmaceuticals shares in Q1 2026, an estimated $741K.
  • Vertex Pharmaceuticals made up 0.1% of Nisa Investment Advisors's portfolio in Q1 2026, its #133 holding.
  • Nisa Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Nisa Investment Advisors's Vertex Pharmaceuticals position peaked at $37.8M in Q2 2020.
  • 1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.